Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Open Access
- 31 July 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (11), e214
- https://doi.org/10.1136/annrheumdis-2020-218627
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- COVID-19, Arrhythmic Risk, and InflammationCirculation, 2020
- Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)JAMA Cardiology, 2020
- Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, ItalyEuropean Journal of Internal Medicine, 2020
- COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmiasHeart Rhythm, 2020
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyEuropean Journal of Internal Medicine, 2020
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumoniaEuropean Journal of Internal Medicine, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020
- Perforación intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides. A propósito de un casoCirugía Española, 2020
- Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)Mayo Clinic Proceedings, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020